CytomX Therapeutics (CTMX) to Release Quarterly Earnings on Wednesday

CytomX Therapeutics (NASDAQ:CTMX) will be releasing its earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.03) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Monday, March 11th. The biotechnology company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.01). The business had revenue of $26.61 million during the quarter, compared to analyst estimates of $23.36 million. On average, analysts expect CytomX Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CytomX Therapeutics Stock Down 2.7 %

CytomX Therapeutics stock traded down $0.12 during midday trading on Tuesday, reaching $4.25. 744,347 shares of the company traded hands, compared to its average volume of 3,484,419. The business has a 50 day moving average of $2.31 and a two-hundred day moving average of $1.74. CytomX Therapeutics has a 12 month low of $1.04 and a 12 month high of $5.85.

Analysts Set New Price Targets

CTMX has been the subject of a number of recent research reports. Jefferies Financial Group upgraded CytomX Therapeutics from a “hold” rating to a “buy” rating and boosted their price target for the company from $2.50 to $8.00 in a research note on Monday. BMO Capital Markets restated a “market perform” rating and issued a $3.25 price target on shares of CytomX Therapeutics in a research report on Wednesday, May 1st. StockNews.com downgraded CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, April 23rd. Finally, JPMorgan Chase & Co. raised shares of CytomX Therapeutics from an “underweight” rating to a “neutral” rating in a report on Monday, April 22nd. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $4.75.

Insider Buying and Selling at CytomX Therapeutics

In other news, CEO Sean A. Mccarthy sold 20,223 shares of CytomX Therapeutics stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $2.09, for a total value of $42,266.07. Following the sale, the chief executive officer now directly owns 524,481 shares of the company’s stock, valued at $1,096,165.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders have sold 35,024 shares of company stock worth $73,200. Insiders own 7.00% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.